JP2017507175A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507175A5 JP2017507175A5 JP2016568089A JP2016568089A JP2017507175A5 JP 2017507175 A5 JP2017507175 A5 JP 2017507175A5 JP 2016568089 A JP2016568089 A JP 2016568089A JP 2016568089 A JP2016568089 A JP 2016568089A JP 2017507175 A5 JP2017507175 A5 JP 2017507175A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- cancer
- compound
- compound according
- ome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 2
- 206010003445 Ascites Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461937368P | 2014-02-07 | 2014-02-07 | |
| US61/937,368 | 2014-02-07 | ||
| US201461987323P | 2014-05-01 | 2014-05-01 | |
| US61/987,323 | 2014-05-01 | ||
| PCT/AU2015/050040 WO2015117202A1 (en) | 2014-02-07 | 2015-02-05 | Functionalised benzopyran compounds and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017507175A JP2017507175A (ja) | 2017-03-16 |
| JP2017507175A5 true JP2017507175A5 (enExample) | 2018-02-22 |
| JP6570042B2 JP6570042B2 (ja) | 2019-09-04 |
Family
ID=53777071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568089A Active JP6570042B2 (ja) | 2014-02-07 | 2015-02-05 | 官能化ベンゾピラン化合物およびその使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9701655B2 (enExample) |
| EP (1) | EP2953938B1 (enExample) |
| JP (1) | JP6570042B2 (enExample) |
| KR (1) | KR102395543B1 (enExample) |
| CN (2) | CN108484559A (enExample) |
| AU (1) | AU2015213484B2 (enExample) |
| BR (1) | BR112016018099B8 (enExample) |
| CA (1) | CA2936012C (enExample) |
| CL (1) | CL2016001937A1 (enExample) |
| DK (1) | DK2953938T3 (enExample) |
| ES (1) | ES2643407T3 (enExample) |
| IL (1) | IL241515B (enExample) |
| LT (1) | LT2953938T (enExample) |
| MX (1) | MX368063B (enExample) |
| MY (1) | MY195739A (enExample) |
| NZ (1) | NZ711603A (enExample) |
| PH (1) | PH12016501422B1 (enExample) |
| PL (1) | PL2953938T3 (enExample) |
| PT (1) | PT2953938T (enExample) |
| RU (1) | RU2676766C2 (enExample) |
| SA (1) | SA516371583B1 (enExample) |
| SG (2) | SG11201604490SA (enExample) |
| SI (1) | SI2953938T1 (enExample) |
| WO (1) | WO2015117202A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201604490SA (en) * | 2014-02-07 | 2016-07-28 | Novogen ltd | Functionalised benzopyran compounds and use thereof |
| HUE054998T2 (hu) | 2015-02-02 | 2021-10-28 | Mei Pharma Inc | Kombinációs terápiák emlõrák kezelésében való alkalmazásra |
| US10265294B2 (en) * | 2016-03-31 | 2019-04-23 | Yale University | Compositions and methods for treating epithelial cancer |
| CA3058492A1 (en) * | 2016-04-06 | 2017-10-12 | Noxopharm Limited | Radiotherapy improvements |
| JP2019513828A (ja) | 2016-04-06 | 2019-05-30 | ノクソファーム リミティド | 改善された薬物動態を有するイソフラボノイド組成物 |
| CN106943397B (zh) * | 2017-03-01 | 2020-08-04 | 浙江大学 | 雄激素受体拮抗剂及其应用 |
| AU2021247415A1 (en) | 2020-03-30 | 2022-09-29 | Noxopharm Limited | Methods for the treatment of inflammation associated with infection |
| US20230233519A1 (en) * | 2020-06-11 | 2023-07-27 | Mei Pharma, Inc. | Combination therapies |
| WO2023235929A1 (en) * | 2022-06-08 | 2023-12-14 | Noxopharm Limited | Functionalised benzopyran compounds and uses thereof |
| CN118005594B (zh) * | 2023-05-24 | 2024-10-29 | 内蒙古大学 | 3-羟基苯并二氢吡喃衍生物的合成及其抗肿瘤活性 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3340276A (en) | 1964-04-01 | 1967-09-05 | Ciba Geigy Corp | 3, 4-diphenyl-chromans |
| US3822287A (en) | 1969-04-17 | 1974-07-02 | Rexall Drug Chemical | Process for preparation of substituted 3,4-(diphenyl)chromans |
| US4447622A (en) | 1981-09-22 | 1984-05-08 | Council Of Scientific And Industrial Research Rafi Marg | Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof |
| BE891562A (fr) | 1981-12-21 | 1982-04-16 | Council Scient Ind Res | Isomeres 1 et d de d1-3, 4-trans-3, 4-diarylchromanes 2, 2-disubstitues et leurs derives, leur preparation et leur utilisation |
| US5451603A (en) | 1993-03-11 | 1995-09-19 | Zymogenetics, Inc. | 3,4-diarylchromans for treatment of dermatitis |
| US5280040A (en) | 1993-03-11 | 1994-01-18 | Zymogenetics, Inc. | Methods for reducing bone loss using centchroman derivatives |
| CA2208868A1 (en) | 1995-01-13 | 1996-07-18 | Novo Nordisk A/S | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of idiopathic or physiologic gynaecomastia |
| HUP9702244A3 (en) | 1995-01-13 | 1999-12-28 | Novo Nordisk As | Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders |
| HUP9800521A3 (en) | 1995-01-13 | 1999-12-28 | Novo Nordisk As | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or propylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis |
| AU4329196A (en) | 1995-01-20 | 1996-08-07 | Novo Nordisk A/S | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis |
| TW448046B (en) | 1995-01-20 | 2001-08-01 | Novo Nordisk As | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity |
| KR19980701549A (ko) | 1995-01-20 | 1998-05-15 | 슈타르 피아 | 퇴행성 뇌질환의 치료 또는 예방용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 이용(use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of cerebral degenerative disorders) |
| CN1207038A (zh) | 1996-01-11 | 1999-02-03 | 诺沃挪第克公司 | 3,4－二苯基苯并二氢吡喃在生产预防或治疗绝经症状的药物组合物中的应用 |
| US5747059A (en) | 1996-01-11 | 1998-05-05 | Novo Nordisk A/S | Atrophy of skin/mucous membrane |
| IL124882A0 (en) | 1996-01-11 | 1999-01-26 | Novo Nordisk As | Use of 3, 4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms |
| US5883118A (en) | 1996-01-11 | 1999-03-16 | Nova Nordisk A/S | Prostatic carcinoma |
| US5726202A (en) | 1996-01-11 | 1998-03-10 | Novo Nordisk A/S | Benign prostatic hypertrophy |
| US5756539A (en) | 1996-07-11 | 1998-05-26 | Novo Nordis A/S | 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders |
| US5780502A (en) | 1996-07-12 | 1998-07-14 | Novo Nordisk A/S | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome |
| CA2270113A1 (en) * | 1996-10-28 | 1998-05-07 | Poul Jacobsen | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
| US5925771A (en) | 1996-10-28 | 1999-07-20 | Novo Nordisk A/S | Process for the preparation of (-)-3,4-trans-diarylchromans |
| US6043269A (en) | 1996-10-28 | 2000-03-28 | Novo Nordisk A/S | cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
| US5919817A (en) | 1996-10-28 | 1999-07-06 | Novo Nordisk A/S | Cis-3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
| JP2001502704A (ja) | 1996-10-28 | 2001-02-27 | ノボ ノルディスク アクティーゼルスカブ | エストロゲン関連疾患又は症候群の予防又は処置において有用な新規ｃｉｓ―３，４―クロマン誘導体の新規の（―）―鏡像異性体 |
| AU5550298A (en) | 1997-01-29 | 1998-08-25 | Novo Nordisk A/S | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical compositionfor increasing libido in post-menopausal women |
| ZA98681B (en) | 1997-01-29 | 1998-07-29 | Novo Nordisk As | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibition senescense-associated motor impairment |
| US6184005B1 (en) | 1998-04-28 | 2001-02-06 | Novo Nordisk A/S | Enzymatic resolvation for obtaining a (−)-3,4-trans-diarylchroman |
| EP1115398B1 (en) * | 1998-09-23 | 2010-05-05 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| AU6315300A (en) | 1999-07-26 | 2001-02-13 | Shionogi & Co., Ltd. | Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same |
| WO2002030407A1 (en) | 2000-10-13 | 2002-04-18 | Astrazeneca Ab | ESTROGEN RECEPTOR-β LIGANDS |
| US20050119301A1 (en) | 2001-03-16 | 2005-06-02 | Alan Husband | Treatment of restenosis |
| JP4256679B2 (ja) | 2001-03-16 | 2009-04-22 | ノボゲン リサーチ ピーティーワイ リミテッド | 再狭窄の治療方法 |
| JP2005524630A (ja) | 2002-01-14 | 2005-08-18 | ノルディック・ビオサイエンス・エー／エス | エストロゲン受容体を介する軟骨破壊の抑制 |
| US20040167165A1 (en) | 2003-01-16 | 2004-08-26 | Geetha Shankar | Methods of treating conditions associated with an Edg-7 receptor |
| US20060141591A1 (en) | 2003-06-04 | 2006-06-29 | Youichi Kyuuko | Method for producing optically active chroman-carboxylate |
| JP2007525485A (ja) | 2003-11-19 | 2007-09-06 | ノボゲン リサーチ ピーティーワイ リミテッド | 複合的な放射線治療及び化学治療の組成物及び方法 |
| WO2006032086A1 (en) | 2004-09-21 | 2006-03-30 | Novogen Research Pty Ltd | Chroman derivatives, medicaments and use in therapy |
| JP4976649B2 (ja) | 2004-09-21 | 2012-07-18 | マーシャル エドワーズ，インク． | 化合物 |
| US8080675B2 (en) | 2004-09-21 | 2011-12-20 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
| EP2407462B1 (en) | 2004-09-21 | 2014-07-30 | Marshall Edwards, Inc. | Substituted chroman derivatives, medicaments and use in therapy |
| ES2377073T3 (es) * | 2004-09-21 | 2012-03-22 | Marshall Edwards, Inc. | Derivados de cromano sustituidos, medicamentos y utilización en terapia |
| US7528267B2 (en) | 2005-08-01 | 2009-05-05 | Girindus America, Inc. | Method for enantioselective hydrogenation of chromenes |
| WO2007096362A1 (en) | 2006-02-21 | 2007-08-30 | Trigen Limited | Heterocyclic compounds and their use in the treatment of cardiovascular disease |
| EP2084141A4 (en) | 2006-10-30 | 2010-07-21 | Novogen Res Pty Ltd | Prevention and reversal of chemotherapy-induced peripheral neuropathy |
| CN101210012B (zh) | 2006-12-31 | 2011-09-14 | 南华大学 | 新的含烟酸异黄酮酯衍生物及其制造方法和用途 |
| US20120039917A1 (en) | 2008-08-29 | 2012-02-16 | Alan James Husband | Immunomodulating activities |
| EP2362773A4 (en) | 2008-10-22 | 2012-05-09 | Novogen Res Pty Ltd | METHOD FOR TRIGGERING PROGRAMMED CELL DEATH |
| AU2008230055A1 (en) | 2008-10-22 | 2010-05-06 | Novogen Research Pty Ltd | Methods for Inducing Programmed Cell Death |
| US8952054B2 (en) | 2010-03-15 | 2015-02-10 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of MUC1 and methods of identifying the same |
| WO2011156889A1 (en) | 2010-06-14 | 2011-12-22 | Trt Pharma Inc. | Novel modulators of nrf2 and uses thereof |
| EP2635121B1 (en) * | 2010-11-01 | 2020-01-08 | MEI Pharma, Inc. | Isoflavonoid compounds and methods for the treatment of cancer |
| CN102153535A (zh) | 2011-03-04 | 2011-08-17 | 中国海洋大学 | 一种抗肿瘤多药耐药抑制剂苯并吡喃-3-醇酯化衍生物及其制备方法和应用 |
| US20120251630A1 (en) | 2011-03-29 | 2012-10-04 | Marshall Edwards, Inc. | Remission therapy of cancer with isoflavonoids |
| US20150018566A1 (en) * | 2011-08-25 | 2015-01-15 | The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy | Tubulin binding agents |
| CN104870438A (zh) | 2012-06-07 | 2015-08-26 | 佐治亚州立大学研究基金会公司 | Seca抑制剂以及其制备和使用方法 |
| CN103408528B (zh) | 2013-08-13 | 2015-04-29 | 浙江大学 | 一种色满化合物及其制备方法和应用 |
| CN103450142B (zh) | 2013-09-04 | 2015-03-25 | 浙江大学 | 一种色满化合物及其提取方法和应用 |
| CN103585145A (zh) | 2013-11-28 | 2014-02-19 | 常州科立信医疗器械有限公司 | Artoxanthochromane在治疗前列腺癌药物中的应用 |
| CN103690525A (zh) | 2013-12-02 | 2014-04-02 | 常州科立信医疗器械有限公司 | Artoxanthochromane在治疗舌癌药物中的应用 |
| CN103638008B (zh) | 2013-12-02 | 2015-09-16 | 刘艳娇 | Artoxanthochromane在治疗皮肤癌药物中的应用 |
| CN103705503A (zh) | 2013-12-04 | 2014-04-09 | 常州科立信医疗器械有限公司 | Artoxanthochromane在治疗乳腺癌药物中的应用 |
| SG11201604490SA (en) * | 2014-02-07 | 2016-07-28 | Novogen ltd | Functionalised benzopyran compounds and use thereof |
-
2015
- 2015-02-05 SG SG11201604490SA patent/SG11201604490SA/en unknown
- 2015-02-05 DK DK15746211.0T patent/DK2953938T3/en active
- 2015-02-05 ES ES15746211.0T patent/ES2643407T3/es active Active
- 2015-02-05 SG SG11201506988TA patent/SG11201506988TA/en unknown
- 2015-02-05 BR BR112016018099A patent/BR112016018099B8/pt active IP Right Grant
- 2015-02-05 MX MX2016010137A patent/MX368063B/es active IP Right Grant
- 2015-02-05 MY MYPI2016702471A patent/MY195739A/en unknown
- 2015-02-05 CN CN201810378034.2A patent/CN108484559A/zh active Pending
- 2015-02-05 WO PCT/AU2015/050040 patent/WO2015117202A1/en not_active Ceased
- 2015-02-05 JP JP2016568089A patent/JP6570042B2/ja active Active
- 2015-02-05 KR KR1020167021722A patent/KR102395543B1/ko active Active
- 2015-02-05 NZ NZ711603A patent/NZ711603A/en unknown
- 2015-02-05 EP EP15746211.0A patent/EP2953938B1/en active Active
- 2015-02-05 PL PL15746211T patent/PL2953938T3/pl unknown
- 2015-02-05 CN CN201580002687.5A patent/CN105980372B/zh active Active
- 2015-02-05 CA CA2936012A patent/CA2936012C/en active Active
- 2015-02-05 LT LTEP15746211.0T patent/LT2953938T/lt unknown
- 2015-02-05 PT PT157462110T patent/PT2953938T/pt unknown
- 2015-02-05 RU RU2016133731A patent/RU2676766C2/ru active
- 2015-02-05 SI SI201530099T patent/SI2953938T1/en unknown
- 2015-02-05 AU AU2015213484A patent/AU2015213484B2/en active Active
- 2015-02-05 US US14/771,440 patent/US9701655B2/en active Active
- 2015-09-10 IL IL241515A patent/IL241515B/en active IP Right Grant
-
2016
- 2016-07-19 PH PH12016501422A patent/PH12016501422B1/en unknown
- 2016-07-31 SA SA516371583A patent/SA516371583B1/ar unknown
- 2016-08-01 CL CL2016001937A patent/CL2016001937A1/es unknown
-
2017
- 2017-06-05 US US15/613,711 patent/US10370349B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507175A5 (enExample) | ||
| JP2012153722A5 (enExample) | ||
| JP2015078199A5 (enExample) | ||
| JP2014508811A5 (enExample) | ||
| CN109715626A (zh) | 作为fgfr抑制剂的杂环化合物 | |
| JP2018525441A5 (enExample) | ||
| MX2021001583A (es) | Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso. | |
| JP2013502441A5 (enExample) | ||
| BR112018072872A2 (pt) | compostos de 1-tetra-hidropiranilcarbonil-2,3-di-hidro-1h-indol para tratar câncer | |
| PH12016500169A1 (en) | Polymorph of syk inhibitors | |
| JP2016538344A5 (enExample) | ||
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| MX395148B (es) | Método para sintetizar los análogos de hormona tiroidea y leucocitos polimorfonucleares de los mismos. | |
| RU2016133731A (ru) | Функционализованные соединения бензопирана и их применение | |
| EA201691342A1 (ru) | Пиразолоновые соединения и их применение | |
| JP2016503414A5 (enExample) | ||
| NZ718487A (en) | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof | |
| JP2019534865A5 (enExample) | ||
| TN2015000445A1 (en) | Derivatives of dolastatin 10 and auristatins | |
| JP2017526662A5 (enExample) | ||
| MY189345A (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| JP2017524013A5 (enExample) | ||
| MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
| JP2016528273A5 (enExample) | ||
| JP2018525425A5 (enExample) |